Login to Your Account

Ariad Gets $75 Million Up Front In Merck Deal On mTOR Inhibitor

By Trista Morrison

Friday, July 13, 2007
With its lead candidate AP23573 poised to begin Phase III trials in metastatic sarcoma, Ariad Pharmaceuticals Inc. signed a global development and commercialization partnership for the small-molecule mTOR inhibitor with Merck and Co. Inc. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription